Publications

5543 Results

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Patients with Early-Stage Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;S Smith;B Schneider;W Irvin;A Hathaway;A Vander Woude;V Gudena;P Cabrera-Galean;M Orsted;M LeBlanc;NL Henry;MJ Fisch
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral; J Clin Oncol 42, 2024 (suppl 16; abstr 12005)
Year
2024
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1714

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;H Pathak;J Gralow;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;P Rastogi;A Schott;S Shak;D Tripathy;G Hortobagyi;F Meric-Bernstam;P Sharma;L Pusztai;A Thompson;A Godwin
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation; J Clin Oncol 42, 2024 (suppl 16; abstr 505)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)

Authors
Y Chae;E Dietrich;M Othus;L Il-Young Chung;H Kim;C Ryan;CD Blanke;S Patel;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 2514)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

SWOG S2107 - Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Authors
VK Morris;KA Guthrie;ES Kopetz;R Breakstone;T Karasic;I Hu;S Colby;M Fakih;S Gholami;PJ Gold;EG Chiorean;PA Philip
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS3640)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107

Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer: Findings from the CALGB/SWOG 80405 (Alliance)

Authors
E Cheng;F Ou;C Ma;A Venook;H-J Lenz;E O'Reilly;P Campbell;C Kuang;B Caan;K Ng;J Meyerhardt
Journal / Conference
AACR Annual Meeting (April 5-10, 2024, San Diego, CA), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Sarcomatoid Lung Cohort #11

Authors
Y Chae;M Othus;S Patel;P Sandhu;L Corum;J Cetnar;S Rayani;L Il-Young Chung;M Chansky;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
AACR Annual Meeting (April 5-10, 2024, San Diego, CA), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Biopsy analysis in S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma

Authors
K Campbell;Z Bustami;D Chen;E Medini;J Maxey;C Gonzalez;N Naser Al Deen;I Baselga Carretero;A Vega-Crespo;J Ming Chen;L Kuklinski;K Kendra;B Chmielowski;T Truong;N Khushalani;F Collichio;A Ikeguchi;A Victor;K Margolin;J Sosman;S Patel;S Hu-Lieskovan;J Moon;S Bellasea;C Spencer;M Thompson;M Wu;A Vanderwalde;P Scumpia;A Ribas
Journal / Conference
AACR Annual Meeting (April 5-10, 2023, San Diego, CA), oral
Year
2024
Research Committee(s)
Melanoma
Study Number(s)
S1616

Expanding the Use of Artificial Intelligence while Protecting Data Privacy in Clinical Trials

Authors
C Cook;A Hoering;M LeBlanc
Journal / Conference
Society for Ciinical Trials (SCT) (May19-22, 2024, Boston, MA), oral
Year
2024
Research Committee(s)
Cancer Care Delivery

Decoding biomarkers of immune activation in neuroendocrine carcinomas treated with ipilimumab and nivolumab using a multiomic approach

Authors
C Haymaker;G Kumar;Y Chae;E Gonzalez-Koslova;C Dualt;J Zhang;M Othus;L Soto;G Manyam;P Jiang;E Cuentas;C Fernandez;A Reuben;H Maecker;S Gnjatic;G al-Atrash;J Zhang;J Lee;S Patel;R Kurzrock
Journal / Conference
ESMO Sarcoma and Rare Cancers Congress (March 14-16, 2024 Lugano, Switzerland), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A randomized trial of the addition of ruxolitinib to BCR::ABL1 tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) with molecular evidence of disease (SWOG trial S1712)

Authors
K Sweet;M Othus;S Tantravahi;J Radich;J Thompson;J Mendler;C Boddy;P Kumar;E Attalah;U Perepu;J Pinilla-Ibarz;A Moseley;H Erba
Journal / Conference
European Hematology Association Hybrid Congress (June 13-16, Madrid Spain) (EHA), oral
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
S1712